Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals

Autor: Marjorie Pion, Carmen Camara, Maria Pilar Rojo-Portoles, Cecilia Berin, Lucía del Pino-Molina, Rafael Correa-Rocha, Antonio Bertoletti, Eduardo López-Granados, Alberto Ortiz, Jordi Ochando, Isabel Cervera, José Portolés, Irene Bodega-Mayor, Anthony T. Tan, Estela Paz-Artal, Mayte Pérez-Olmeda, Maria Gonzalez-Perez, Manisha Brahmachary, Luz Yadira Bravo-Gallego, Rodrigo Sanchez-Tarjuelo, Venu Pothula, Pilar Nozal, Ernesto Guccione, María Montes-Casado, Marta Erro Iribarren, Marcos López-Hoyos, Nina Le Bert, Daniel Lozano-Ojalvo, Pilar Portolés, Jesús Oteo, Gloria Ojeda, Megan C. Schwarz
Přispěvatelé: Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación (España), NIH - National Cancer Institute (NCI) (Estados Unidos), Icahn School of Medicine at Mount Sinai, Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF), Gobierno de Cantabria (España), Unión Europea. Comisión Europea. H2020, National Institutes of Health (Estados Unidos), National Institutes of Health (US), American Institute for Cancer Research, Gobierno de Cantabria, Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), European Commission, Lozano-Ojalvo, D., Guccione, Ernesto, Universidad de Cantabria, Lozano-Ojalvo, D. [0000-0002-3524-2929], Guccione, Ernesto [0000-0001-7764-5307]
Jazyk: angličtina
Předmět:
Cellular immunity
T-Lymphocytes
Antibodies
Viral
T-cell immunity
0302 clinical medicine
Medicine
030212 general & internal medicine
050207 economics
Respiratory system
Biology (General)
media_common
0303 health sciences
Immunity
Cellular
Vaccines
Synthetic
050208 finance
05 social sciences
Vaccination
Institutional review board
3. Good health
Spike Glycoprotein
Coronavirus
medicine.medical_specialty
COVID-19 Vaccines
Coronavirus disease 2019 (COVID-19)
QH301-705.5
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
CD40 Ligand
General Biochemistry
Genetics and Molecular Biology
03 medical and health sciences
Interferon-gamma
Immunity
Report
0502 economics and business
media_common.cataloged_instance
Humans
European union
030304 developmental biology
Messenger RNA
BNT162b2 vaccine
business.industry
SARS-CoV-2
COVID-19
biochemical phenomena
metabolism
and nutrition
Immunity
Humoral
Regimen
Immunization
Family medicine
Immunoglobulin G
Immunology
Interleukin-2
business
Peptides
Zdroj: Cell Reports
Repisalud
Instituto de Salud Carlos III (ISCIII)
Cell Reports, Vol 36, Iss 8, Pp 109570-(2021)
Cell Rep . 2021 Aug 24;36(8):109570
UCrea Repositorio Abierto de la Universidad de Cantabria
Universidad de Cantabria (UC)
Digital.CSIC. Repositorio Institucional del CSIC
instname
ISSN: 2211-1247
DOI: 10.1016/j.celrep.2021.109570
Popis: The rapid development of mRNA-based vaccines against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) led to the design of accelerated vaccination schedules that have been extremely effective in naive individuals.While a two-dose immunization regimen with the BNT162b2 vaccine has been demonstrated to provide a 95% efficacy in naive individuals, the effects of the second vaccine dose in individuals who have previously recovered from natural SARS-CoV-2 infection has not been investigated in detail. In this study, we characterize SARS-CoV-2 spike-specific humoral and cellular immunity in naive and previously infected individuals during and after two doses of BNT162b2 vaccination. Our results demonstrate that, while the second dose increases both the humoral and cellular immunity in naive individuals, COVID-19 recovered individuals reach their peak of immunity after the first dose. These results suggests that a second dose, according to the current standard regimen of vaccination, may be not necessary in individuals previously infected with SARS-CoV-2.
Research reported in this publication was supported in part by the National Cancer Institute of the NIH (5R01HD102614-02; R01CA249204 and R01CA248984) and an ISMMS seed fund to E.G. The authors gratefully acknowledge use of the services and facilities of the Tisch Cancer Institute supported by a NCI Cancer Center Support Grant (P30 CA196521). M.S. was supported by a NCI training grant (T32CA078207). This work was supported by an ISMMS seed fund to J.O.; Instituto de Salud Carlos III (COV20-00668) to R.C.R.; the Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation (COVID-19 research call COV20/00181) co-financed by the European Development Regional Fund “A way to achieve Europe” to E.P.; the Instituto de Salud Carlos III, Spain (COV20/00170); the Government of Cantabria, Spain (2020UIC22-PUB-0019) to M.L.H.; the Instituto de Salud Carlos III (PI16CIII/00012) to P.P.; the Fondo Social Europeo e Iniciativa de Empleo Juvenil YEI (Grant PEJ2018-004557-A) to M.P.E.; and by REDInREN 016/009/009 ISCIII. This project has received funding from the European Union Horizon 2020 research and innovation programs VACCELERATE and INsTRuCT under grant agreements 101037867 and 860003.
Databáze: OpenAIRE
Externí odkaz: